Navigation Links
Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
Date:5/29/2013

KALAMAZOO, Mich., May 29, 2013 /PRNewswire/ -- Metabolic Solutions Development Company, LLC (MSDC) announced today the publication of data in a recent issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0062012) on the effects of a new drug for type 2 diabetes in restoring insulin sensitivity and insulin content in human beta- (b-) cells.  Researchers at Washington University in St. Louis, led by Michael McDaniel , PhD, and Nidhi Rohatgi , PhD, found this next generation insulin sensitizer may provide physicians with a new tool for the treatment of diabetes that relieves insulin resistance in human islets, thereby preserving the survival and function of human beta-cells.

Beta-cells are produced in regions in the pancreas referred to as "islets". Their function is to produce, store and release insulin, a hormone essential to the efficient utilization of glucose, a type of sugar that comes from carbohydrate foods and that is the body's main source of energy.[1] In patients with type 2 diabetes, beta-cell death is increased and the number of beta-cells is reduced. In addition, their function may have declined by as much as 80 percent by the time treatment is initiated,[2] resulting in lower insulin levels and higher glucose levels.  In this laboratory study, researchers found that direct treatment of cultured human islets with a new drug for the treatment of type 2 diabetes, MSDC-0160, produced a unique modulation of nutrient sensors that restored normal cell communication mechanisms and enabled the survival and preservation of human beta-cell function, including insulin content.

Diabetes is an undertreated global epidemic affecting an estimated 340 million people worldwide, with a rapidly increasing incidence throughout the developed and developing world. In the United States alone, nearly 26 million adults and children live with the disease. An additional 79 million have pre-diabetes, placing them at increased risk for developing type 2 diabetes. Recently published research by the American Diabetes Association estimates the total costs of diagnosed diabetes have risen to $245 billion in 2012 from $174 billion in 2007, when the cost was last examined. This figure represents a 41 percent increase over a five-year period.

MSDC-0160, a prototype mTOT modulator developed by MSDC, exerts its insulin sensitizing effects through a recently identified mitochondrial protein complex called mTOT™ (mitochondrial target of thiazolidinediones).[3] Data suggest mTOT functions as a molecular sensor switch that coordinates carbohydrate, lipid, and amino acid metabolism with cell function. In addition to preserving beta-cell function as observed in human islets, mTOT modulators have been shown in animal models of type 2 diabetes to improve insulin signaling, decrease calorie-storing "white fat," and increase levels of calorie burning "brown fat."

Recently published Phase 2b clinical data from a study[4] in 258 type 2 diabetic patients further demonstrate modulating mTOT could constitute a new approach for the discovery and development of potentially more useful and novel insulin sensitizers.

About Metabolic Solutions Development Company
Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company investigating novel molecular targets and developing new therapeutics to treat metabolic diseases associated with age-related mitochondrial dysfunction, especially type 2 diabetes.

[1] http://diabetes.webmd.com/blood-glucose.

[2] DeFronzo, RA. Diabetes, Vol. 58, April 2009, pp. 773-795.

[3] http://dx.plos.org/10.1371/journal.pone.0061551: "Identification of a Mitochondrial Target of Thiazolidinedione Insulin Sensitizers (mTOT) - relationship to newly identified mitochondrial pyruvate carrier proteins."

[4] Colca, et al. Clinical Proof-of-Concept Study With MSDC-0160, a Prototype mTOT-Modulating Insulin Sensitizer. Clinical Pharmacology & Therapeutics doi:10.1038/clpt.2013.10 .


'/>"/>
SOURCE Metabolic Solutions Development Company, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unigene and Nordic Bioscience Enter Equity Transfer and Exclusive License Agreement for Proprietary Metabolic Peptide Analogs
2. Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
3. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
4. Metabolic Solutions Development Company Awarded Funding by The Michael J. Fox Foundation
5. Metabolic Solutions Development Company announces publication of Phase 2b data in Clinical Pharmacology & Therapeutics
6. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
7. Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Demonstrates Potential Anticancer Activity in Various Metastatic Sarcomas and Bladder Cancers That Are Deficient in Key Metabolic Protein, and Enhanced Effects with Combination Therapy in Melanoma
8. Profil Institute Partners with Florida Hospital to Establish East Coast Center for Clinical Metabolic Research
9. BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
10. Medifirst Solutions, Inc. Announces Update To Shareholders
11. Life Line Screening and MCM Solutions for Better Health Announce New Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 24, 2016 , ... Southern Illinois University School of Dental ... Illinois State Dental Society (ISDS) Foundation’s Mission of Mercy (MOM). They will host ... Collinsville. , They expect to treat approximately 2,000 patients from Illinois, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... a not-for-profit organization responsible for clinical transfusion research programs and for the blood ... Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently ...
(Date:6/23/2016)... ... June 23, 2016 , ... SyncDog, Inc. , ... security software, is featured in the current issue of Silicon Review ... with innovative technology solutions and features them in their magazine. The magazine allows ...
(Date:6/23/2016)... ... 23, 2016 , ... Horizon Blue Cross Blue Shield of ... from the crushing burden of sky-high health care costs, Superior Court of New ... ( http://www.judiciary.state.nj.us/opinions/a2913-15a2929-15.pdf ) the court provided some analysis of the contracts between ...
(Date:6/23/2016)... ... ... A key metric of this success is the popularity of the Leafedin.org service ... areas that lack the kind of technology and networking framework that LeafedIn.org provide, where ... the marijuana industry, no matter how small or large, and more importantly no matter ...
Breaking Medicine News(10 mins):